Cantor Fitzgerald reissued their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report sent to investors on Friday morning. Cantor Fitzgerald currently has a $50.00 price objective on the biotechnology company’s stock.
“Yesterday, Pulse Biosciences (PLSE; Not Covered) presented data from two human skin studies (dose-response study & first clinical use study) using NPS technology as potential treatment for SK. We do not think the data are meaningfully important to ACRS for a few reasons, listed below.”,” Cantor Fitzgerald’s analyst wrote.
A number of other research firms have also weighed in on ACRS. BidaskClub lowered shares of Aclaris Therapeutics from a hold rating to a sell rating in a research report on Wednesday, December 20th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a sell rating to a hold rating in a research report on Monday, February 19th. Leerink Swann lowered their price target on shares of Aclaris Therapeutics from $54.00 to $52.00 and set an outperform rating on the stock in a research report on Wednesday, March 28th. Finally, Guggenheim started coverage on shares of Aclaris Therapeutics in a research note on Thursday, February 8th. They set a buy rating and a $53.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $43.50.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.10. The business had revenue of $1.00 million for the quarter, compared to analyst estimates of $0.80 million. sell-side analysts forecast that Aclaris Therapeutics will post -4.27 EPS for the current year.
In other news, insider Neal Walker bought 10,000 shares of Aclaris Therapeutics stock in a transaction on Thursday, April 5th. The shares were bought at an average cost of $16.75 per share, with a total value of $167,500.00. Following the completion of the purchase, the insider now directly owns 897,184 shares of the company’s stock, valued at $15,027,832. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Stephen A. Tullman bought 26,700 shares of Aclaris Therapeutics stock in a transaction on Friday, April 6th. The shares were purchased at an average cost of $16.54 per share, for a total transaction of $441,618.00. Following the completion of the purchase, the director now directly owns 157,507 shares of the company’s stock, valued at $2,605,165.78. The disclosure for this purchase can be found here. Insiders have acquired 37,950 shares of company stock worth $629,856 over the last ninety days. 16.30% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in ACRS. Bank of New York Mellon Corp raised its stake in shares of Aclaris Therapeutics by 24.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 110,015 shares of the biotechnology company’s stock valued at $2,839,000 after acquiring an additional 21,754 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of Aclaris Therapeutics by 49.8% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 92,507 shares of the biotechnology company’s stock valued at $2,388,000 after acquiring an additional 30,742 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in shares of Aclaris Therapeutics in the 3rd quarter valued at approximately $142,000. Rice Hall James & Associates LLC raised its stake in shares of Aclaris Therapeutics by 58.6% in the 4th quarter. Rice Hall James & Associates LLC now owns 65,809 shares of the biotechnology company’s stock valued at $1,623,000 after acquiring an additional 24,325 shares during the period. Finally, Granite Investment Partners LLC purchased a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $565,000. 92.19% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/04/16/aclaris-therapeutics-acrs-earns-buy-rating-from-cantor-fitzgerald.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.